University of Pittsburgh's diabetes treatment technology licensed

A California company has licensed University of Pittsburgh technology, which could become the first effective treatment for a form of diabetes called Type I. San Diego-based DiaVacs Inc. licensed technology developed in 2004 by former UPMC Children's Hospital researchers Massimo Trucco and Nick Giannoukakis. The pair moved their research laboratory along with nearly a dozen other researchers and staff members to Allegheny General Hospital in 2014, where Trucco was named director of the newly created Institute for Cellular Therapeutics. "It's very promising," DiaVacs President and CEO Alan Lewis said about the technology."It's very exciting."